CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Yu, Guang Tao ^a   Bu, Lin Lin ^a   Zhao, Yu Yue ^a   Mao, Liang ^a   Deng, Wei Wei ^a   Wu, Tian Fu ^b   Zhang, Wen Feng ^b   Sun, Zhi Jun ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

CTLA4; HNSCC; immunotherapy; M2 macrophages; MDSCs; myeloid cells

Indexed keywords

9D9; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY; TRANSGENIC ORGANISM; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84976535754     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1151594     Document Type: Article

References (47)

1. M.Hashibe, P.Brennan, S.C.Chuang, S.Boccia, X.Castellsague, C.Chen, M.P.Curado, L.Dal Maso, A.W.Daudt, E.Fabianova et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18:541-50; PMID:19190158; 10.1158/1055-9965.EPI-08-0347
2. C.C.Tong, J.Kao, A.G.Sikora. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 2012; 54:266-74; PMID:22454102; 10.1007/s12026-012-8306-6
3. J.Quan, N.W.Johnson, G.Zhou, P.G.Parsons, G.M.Boyle, J.Gao. Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. Cancer Metastasis Rev 2012; 31:209-19; PMID:22101806; 10.1007/s10555-011-9335-7
4. S.L.Topalian, C.G.Drake, D.M.Pardoll. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; 10.1016/j.ccell.2015.03.001
5. E.A.Tivol, F.Borriello, A.N.Schweitzer, W.P.Lynch, J.A.Bluestone, A.H.Sharpe. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7; PMID:7584144; 10.1016/1074-7613(95)90125-6
6. D.J.Lenschow, K.C.Herold, L.Rhee, B.Patel, A.Koons, H.Y.Qin, E.Fuchs, B.Singh, C.B.Thompson, J.A.Bluestone. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5:285-93; PMID:8808683; 10.1016/S1074-7613(00)80323-4
7. K.S.Hathcock, G.Laszlo, C.Pucillo, P.Linsley, R.J.Hodes. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180:631-40; PMID:7519245; 10.1084/jem.180.2.631
8. K.S.Peggs, S.A.Quezada. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev Anticancer Ther 2010; 10:1697-701; PMID:21080797; 10.1586/era.10.144
9. M.R.Galdiero, E.Bonavita, I.Barajon, C.Garlanda, A.Mantovani, S.Jaillon. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013; 218:1402-10; PMID:23891329; 10.1016/j.imbio.2013.06.003
10. J.C.Ochando, S.H.Chen. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012; 54:275-85; PMID:22535241; 10.1007/s12026-012-8335-1
11. P.Serafini, I.Borrello, V.Bronte. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; 10.1016/j.semcancer.2005.07.005
12. D.T.Weed, J.L.Vella, I.M.Reis, A.C.De la Fuente, C.Gomez, Z.Sargi, R.Nazarian, J.Califano, I.Borrello, P.Serafini. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:39-48; PMID:25320361; 10.1158/1078-0432.CCR-14-1711
13. Y.Liu, X.Cao. The origin and function of tumor-associated macrophages. Cell Mol Immunol 2015; 12:1-4; 10.1038/cmi.2014.83
14. A.Sica, P.Larghi, A.Mancino, L.Rubino, C.Porta, M.G.Totaro, M.Rimoldi, S.K.Biswas, P.Allavena, A.Mantovani. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18:349-55; PMID:18467122; 10.1016/j.semcancer.2008.03.004
15. R.Ostuni, F.Kratochvill, P.J.Murray, G.Natoli. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 2015; 36:229-39; PMID:25770924; 10.1016/j.it.2015.02.004
16. D.R.Rhodes, S.Kalyana-Sundaram, V.Mahavisno, R.Varambally, J.Yu, B.B.Briggs, T.R.Barrette, M.J.Anstet, C.Kincead-Beal, P.Kulkarni et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9:166-80; PMID:17356713; 10.1593/neo.07112
17. S.Trellakis, K.Bruderek, J.Hutte, M.Elian, T.K.Hoffmann, S.Lang, S.Brandau. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun 2013; 19:328-36; PMID:23160385; 10.1177/1753425912463618
18. S.Lyford-Pike, S.Peng, G.D.Young, J.M.Taube, W.H.Westra, B.Akpeng, T.C.Bruno, J.D.Richmon, H.Wang, J.A.Bishop et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733-41; PMID:23288508; 10.1158/0008-5472.CAN-12-2384
19. A.K.Chaturvedi, E.A.Engels, R.M.Pfeiffer, B.Y.Hernandez, W.Xiao, E.Kim, B.Jiang, M.T.Goodman, M.Sibug-Saber, W.Cozen et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301; PMID:21969503; 10.1200/JCO.2011.36.4596
20. L.Sepiashvili, J.P.Bruce, S.H.Huang, B.O'Sullivan, F.F.Liu, T.Kislinger. Novel insights into head and neck cancer using next-generation “omic” technologies. Cancer Res 2015; 75:480-6; PMID:25589349; 10.1158/0008-5472.CAN-14-3124
21. C.R.Leemans, B.J.Braakhuis, R.H.Brakenhoff. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11:9-22; PMID:21160525; 10.1038/nrc2982
22. Y.Bian, B.Hall, Z.J.Sun, A.Molinolo, W.Chen, J.S.Gutkind, C.V.Waes, A.B.Kulkarni. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31:3322-32; PMID:22037217; 10.1038/onc.2011.494
23. C.E.Rudd, A.Taylor, H.Schneider. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26; PMID:19426212; 10.1111/j.1600-065X.2009.00770.x
24. R.D.Schreiber, L.J.Old, M.J.Smyth. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; 10.1126/science.1203486
25. M.Czystowska, W.Gooding, M.J.Szczepanski, A.Lopez-Abaitero, R.L.Ferris, J.T.Johnson, T.L.Whiteside. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res 2013; 19:889-99; PMID:23363813; 10.1158/1078-0432.CCR-12-2191
26. T.L.Walunas, D.J.Lenschow, C.Y.Bakker, P.S.Linsley, G.J.Freeman, J.M.Green, C.B.Thompson, J.A.Bluestone. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; 10.1016/1074-7613(94)90071-X
27. K.F.He, L.Zhang, C.F.Huang, S.R.Ma, Y.F.Wang, W.M.Wang, Z.L.Zhao, B.Liu, Y.F.Zhao, W.F.Zhang et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int 2014; 2014:838632; PMID:24883329; 10.1155/2014/838632.
28. D.Martin, M.C.Abba, A.A.Molinolo, L.Vitale-Cross, Z.Wang, M.Zaida, N.C.Delic, Y.Samuels, J.G.Lyons, J.S.Gutkind. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget 2014; 5:8906-23; PMID:25275298; 10.18632/oncotarget.2417
29. S.Partlova, J.Boucek, K.Kloudova, E.Lukesova, M.Zabrodsky, M.Grega, J.Fucikova, I.Truxova, R.Tachezy, R.Spisek et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 2015; 4:e965570; PMID:25949860; 10.4161/21624011.2014.965570
30. A.Flemming. Cancer: Re-educating tumour-associated macrophages. Nat Rev Drug Discov 2011; 10:177; PMID:21358735; 10.1038/nrd3399
31. J.E.Talmadge, D.I.Gabrilovich. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; 10.1038/nrc3581
32. G.T.Yu, L.L.Bu, C.F.Huang, W.F.Zhang, W.J.Chen, J.S.Gutkind, A.B.Kulkarni, Z.J.Sun. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget 2015; 6:42067-80; PMID:26573233; 10.18632/oncotarget.5955.
33. E.Buchbinder, F.S.Hodi. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125:3377-83; PMID:26325034; 10.1172/JCI80012
34. I.Chevolet, R.Speeckaert, M.Schreuer, B.Neyns, O.Krysko, C.Bachert, B.Hennart, D.Allorge, N.van Geel, M.Van Gele et al. Characterization of the immune network of IDO, tryptophan metabolism, PD-L1, and in circulating immune cells in melanoma. Oncoimmunology 2015; 4:e982382; PMID:25949897; 10.4161/2162402X.2014.982382
35. D.E.Kaufmann, B.D.Walker. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182:5891-7; PMID:19414738; 10.4049/jimmunol.0803771
36. J.G.Egen, M.S.Kuhns, J.P.Allison. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8; PMID:12087419; 10.1038/ni0702-611
37. D.R.Leach, M.F.Krummel, J.P.Allison. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6; PMID:8596936; 10.1126/science.271.5256.1734
38. H.B.Jie, P.J.Schuler, S.C.Lee, R.M.Srivastava, A.Argiris, S.Ferrone, T.L.Whiteside, R.L.Ferris. CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res 2015; 75:2200-10; PMID:25832655; 10.1158/0008-5472.CAN-14-2788
39. M.M.Ewing, J.C.Karper, S.Abdul, R.C.de Jong, H.A.Peters, M.R.de Vries, A.Redeker, J.Kuiper, R.E.Toes, R.Arens et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol 2013; 168:1965-74; PMID:23351788; 10.1016/j.ijcard.2012.12.085
40. C.H.Lee, J.S.Chang, S.H.Syu, T.S.Wong, J.Y.Chan, Y.C.Tang, Z.P.Yang, W.C.Yang, C.T.Chen, S.C.Lu et al. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol 2015; 230:875-84; PMID:25204733; 10.1002/jcp.24816
41. J.J.Oppenheim, C.O.Zachariae, N.Mukaida, K.Matsushima. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu Rev Immunol 1991; 9:617-48; PMID:1910690; 10.1146/annurev.iy.09.040191.003153
42. E.W.Remus, I.Sayeed, S.Won, A.N.Lyle, D.G.Stein. Progesterone protects endothelial cells after cerebrovascular occlusion by decreasing MCP-1- and CXCL1-mediated macrophage infiltration. Exp Neurol 2015; 271:401-8; PMID:26188381; 10.1016/j.expneurol.2015.07.010
43. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; 10.1056/NEJMoa1003466
44. M.S.Swanson, U.K.Sinha. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol 2015; 51:12-5; PMID:25459157; 10.1016/j.oraloncology.2014.10.010
45. T.R.Simpson, F.Li, W.Montalvo-Ortiz, M.A.Sepulveda, K.Bergerhoff, F.Arce, C.Roddie, J.Y.Henry, H.Yagita, J.D.Wolchok et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; 10.1084/jem.20130579
46. G.T.Yu, L.L.Bu, Y.Y.Zhao, B.Liu, W.F.Zhang, Y.F.Zhao, L.Zhang, Z.J.Sun. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2014; 4:764-75; PMID:25520866
47. Z.J.Sun, L.Zhang, B.Hall, Y.Bian, J.S.Gutkind, A.B.Kulkarni. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012; 18:5304-13; PMID:22859719; 10.1158/1078-0432.CCR-12-1371